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Summary 
CD8 + T ceils control immune responses, and recent 
studies suggest that this regulation is, in part, specifi- 
cally directed towards TCR structures expressed by 
CD4 ÷ cells. To develop a system to study the role of 
the TCR in regulatory interactions, we isolated clones 
of CD4 ÷ cells expressing identified TCR VI~ chains. 
These CD4 ÷ clones were used to stimulate and expand 
autologous CD8 ÷ cells, which kill the inducing CD4 ÷ 
clone as well as independently isolated autologous 
CD4 + clones sharing the same TCR Vp as the inducing 
cell but not CD4 ÷ T cells expressing different VJ~ TCRs. 
This Vp-specific cytotoxicity is dependent on the state 
of activation of the target cells and is not inhibited by 
an anti-class I monoclonal antibody, W6/32. We envi- 
sion that Vp-specific CD8 + T cells of this type may 
regulate immune responses by direct interaction with 
antigen-activated CD4 ÷ cells. 
Introduction 
A variety of studies have provided evidence that CD8 ÷ T 
cells interact with CD4 ÷ T Cells to regulate immune re- 
sponses (Bloom et al., 1992a; Eardley et al., 1978; Jandin- 
ski et al., 1976; Thomas et al., 1980). These regulatory 
interactions between CD4 ÷ and CD8 ÷ T cells are complex 
and may involve both antigen-specific as well as nonspe- 
cific mechanisms. In principle, one can envision three dis- 
tinct, but not mutually exclusive, models by which CD8 ÷ 
T cells could specifically regulate antigen-driven CD4 ÷ T 
cells. In the first model, both CD4 ÷ and CD8 ÷ T cells may 
recognize antigen-MHC complexes on conventional anti- 
gen-presenting cells. Because of the proximity of the CD8 ÷ 
cells to the CD4 ÷ cells, the CD8 ÷ T cells could release 
lymphokines that regulate CD4 ÷ T cell function (Bloom et 
al., 1992b; Salgame et al., 1991). In the second model, 
antigen-MHC class II complexes on conventional antigen- 
presenting cells induce CD4 ÷ T cells to acquire a new cell 
surface phenotype defined by the expression of nonpoly- 
morphic membrane molecules unrelated either to antigen 
or to the T cell receptor (TCR), which can be recognized 
by regulatory CD8 ÷ T cells. Because CD4 ÷ T cells are 
known, at least transiently, to express activation antigens, 
these molecules could be used by CD8 ÷ T cells to regulate 
immune response. In the third model, TCR-related struc- 
tures such as TCR-derived peptide-MHC complexes ex- 
pressed on antigen-activated CD4 ÷ cells induce CD8 ÷ reg- 
ulatory cells. In this case, the TCR structures would be 
predicted to bind and be recognized in t~e context of MHC 
class I molecules. These CD8 cells differentiate and recog- 
nize the TCR-derived peptide-MHC class I complexes ex- 
pressed on the activated CD4 ÷ inducer cells. The effector 
phase of regulation mediated by these putative TCR pep- 
tides recognizing CD8 ÷ T cells could either be by direct 
cytolysis, or by the release of cytokines, or both. This view 
of immune regulation was initially suggested, in principle, 
by Jerne (1975) in his idiotypic hypothesis, and many of 
the proposed suppressor cell interaction models proposed 
during the latter part of the 1970s and early 1980s involved 
recognition of TCR structures (Dorf and Benacerraf, 1984; 
Goodman and Sercarz, 1983;Green et al., 1983). 
In this regard, recent experiments in animals strongly 
implicate the TCR variable chains e.~pressed by CD4 ÷ cells 
as being responsible for recognition by regulatory CD8 ÷ 
T cells. For example, injection of mice with superantigen 
is followed by an initial expansion of the T cells characteris- 
tic of the superantigen. This is followed by selective elimi- 
nation, induction, or both, of anergy in these cells (Kawabe 
and Ochi, 1991; McCormack et al., 1993; Rellahan et al., 
1990; Webb et al., 1990). Although various mechanisms 
for the elimination of the respond!rig T cells have been 
suggested, recent studies indicate that CD8 ÷ T cells are 
at least partially involved (Jiang et al., 1995 [this issue of 
Immunity]). Similarly, in experimental allergic encephalo- 
myelitis (EAE), an autoimmune disease induced by CD4 ÷ 
T cells that predominately utilize Vl38.2 TCR molecules 
(Koh et al., 1992), animals that recover spontaneously are 
resistant o relapses and to a second induction of disease 
only if they possess CD8 ÷ T cells (Jidng et al., 1992; Koh 
et al., 1992). In addition, vaccination of rats (Howell et al., 
1989; Vandenbark et al., 1989) andof mice (Gaur et al., 
1992) with a peptide representing' a j~0rtion of VI38.2 also 
confers resistance to EAE. More generally, TCR peptide 
vaccination of mice leads to anergy in the corresponding 
set of CD4 ÷ cells only when CD8 +~ cells are present (Gaur 
et al., 1993). These data suggest thepossibility that CD8 ÷ 
T cells may regulate CD4 ÷ T cells at least in part on the 
basis of CD4 ÷ TCR VI3 chain usagel 
Previous studies in the human immune system have 
also provided evidence that recognition of the TCR is inte- 
gral to the specificity of immune regulation between T cell 
subsets in vitro. For example, a series of experiments have 
shown that it is possible to generate human CD4 ÷ T cell 
clones that proliferate specifically ' to autologous CD4 ÷ 
clones that either show a particular antigen specificity or 
specific VI3 expression (Lamb and Feldman; 1982, Naor 
et al., 1991). In other experiments, human CD8 ÷ T cell 
clones raised to autologous allo-reactive CD4 ÷ cell lines 
have been shown to inhibit fresh autologous CD4 ÷ T cells 
from proliferating to the same alloantigen (Koide and En- 
gleman, 1990). These results were interpreted as being 
consistent with the idea that T-T cell interactions may 
involve all or part of the TCR as a target of recognition. 
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Figure 1. Generation ofCD8 ÷ T Cell Clones that Lyse Autologous VI}2 ÷ 
CD4 + T Cells 
(a) Relative cytotoxicity ofanti-JK50t clones against the inducing clone 
JK50t as compared with the autologous lymphoblastoid l ne. For each 
clone designated on the horizontal axis, the vertical axis represents 
the percent specific cytotoxicity othe inducing clone JK50t, divided 
by the percent specific cytotoxicity othe lymphoblastoid l ne. 
(b) A subclone of JK4/2 was used as an effector against randomly 
selected V62 + CD4 + and Vl}2 CD4 + clones in a 14 hr SlCr release 
assay. 
(c) The same subclone and the CD8 ÷ VI}2 ÷ clone JK214t were used as 
effectors against he inducing clone JK50t and the VI32- CD4 ÷ tetanus- 
toxoid responsive line JK(TT) in a 14 hr S1Cr release assay in the pres- 
ence and absence of TSST-1 (100 ng/ml). The result presented isthe 
average of two independent experiments. 
To develop a system to study more directly the role of 
TCR structures in the interactions of CD8 ÷ cells with CD4 ÷ 
cells in regulating immune responsesl we first isolated 
clones of CD4 ÷ cells expressing identified TCR VI} chains. 
This was accomplished by stimulating purified populations 
of CD4 ÷ cells with either superantigens Or monoclonal anti- 
bodies (MAbs) to known TCR VI3 families. The resultant 
CD4 + cells expressing a given VI3 TCR were then used 
as immunogens to stimulate purified populations of autolo- 
gous CD8 ÷ cells. CD8 ÷ lines and clones obtained in this 
manner were found to recognize specifically and lyse the 
inducing CD4 ÷ clone but not autologous clones or lines 
expressing different TCR V6s. Further analysis of the 
specificity of these CD8 ÷ cells demonstrated that they also 
recognize and kill, to a lesser degree, independently iso- 
lated autologous CD4 ÷ T cell clones and lines expressing 
the same TCR VI} as the inducing clone. This VI}-specific 
cytotoxicity was not blocked by the MAb W6/32, which 
reacts with nonpolymorphic determinants present on HLA 
class I A/B/C molecules. These results demonstrate that 
there are CD8 ÷ T cells present in peripheral blood that 
interact with CD4 ÷ T cells based on CD4 ÷ TCR VI3 usage. 
We envision that cells of this type may have the capacity 
to regulate immune responses by directly killing antigen- 
activated CD4 ÷ inducer clones. 
Results 
Isolation of Human CD8 ÷ Cytotoxic T Lymphocytes 
(CTL) Specific for Autologous CD4 ÷ T Cells 
Expressing TCRs Belonging to Distinct Vp Families 
In the first series of experiments, CD4 ÷ T cell clones were 
isolated from a normal donor (JK) by stimulation of periph- 
eral lymphocytes with the superantigens TSST-1 or SEB, 
which are known to activate T cells expressing mutually 
exclusive sets of TCR VI3 genes (VI32 and VI}3, Vl312, 
VI}14, VI315, VI317, VI320, respectively; Marrack and Kap- 
pier, 1990). These were subcloned using their respective 
superantigens, and representative subclones were subse- 
quently maintained in the absence of feeder cells with 
periodic stimulation by phorbol/ionomycin. One TSST-1 
reactive VI32 ÷ CD4 ÷ clone, JK50t, was used as the inducer 
for production of the autologous CD8 ÷ T cell line, anti- 
JK50t. This line proliferated in response to JK50t and was 
initially shown to lyse JK50t but not an autologous lym- 
phoblastoid cell line. Thirteen clones of this CD8 ÷ line were 
obtained by limiting dilution and screened against the in- 
ducing JK50t clone as well as the autologous lymphoblas- 
told line (Figure la). JK4/2, the most specifically reactive 
against JK50t, was subcloned and tested against a panel 
of independently isolated autologous VI32 + and Vl32- CD4 + 
T cell clones (Figure lb). Reactivity of this subclone was 
greatest oward the inducing clone JK50t, somewhat less 
for other VI32 + CD4 ÷ targets, and lowest for Vl32- CD4 ÷ T 
cells. This result suggests that JK4/2 preferentially recog- 
nizes a structure related to TCR VI32, which is expressed 
on autologous CD4 ÷ T cell clones. 
Although the target cells had been maintained by phar- 
macological stimulation for many generations, we consid- 
ered the possibility that the apparent specificity for V132- 
bearing cells might be owing to small amounts of residual 
superantigen used in their original selection. We therefore 
compared the cytotoxicity of JK4/2 toward VI}2 + CD4 ÷ and 
VI32- CD4 ÷ T cells in the presence and absence of TSST-1 
(Figure lc). As a positive control, we used the CD8 ÷ VI32 ÷ 
T cell clone JK214t, which previously had been shown to 
kill MHC class II-expressing targets in the presence of 
TSST-I. VI32 + CD4 ÷ cells were efficiently killed by JK4/2 
in the absence of TSST-1, and killing was not increased 
in its presence. Furthermore, baseline cytotoxicity toward 
the V~2- CD4 ÷ cells was not augmented in the presence 
of TSST-I. On the other hand, JK214t killed all targets in 
the presence of TSST-1, but not in its absence. Taken 
together, these experiments rule out the possibility that 
carryover of TSST-1 from the original isolation of inducer 
clones contributed significantly to the cytotoxicity of the 
anti-JK50t subclone JK4/2 to the Vl32 + CD4 ÷ cells. 
The fact that the anti-JK50t subclone JK4/2 was cyto- 
toxic not only to the inducing JK50t clone but also to other 
autologous independently isolated VI}2 ÷ CD4 ÷ clones that 
presumably utilized different Vl32 clonotypic determinants, 
but was not cytotoxic to VI}2- CD4 ÷ clones, suggested that 
JK4/2 does not recognize strictly clonotypic sequences 
on the targets. To determine whether this was a feature 
unique to JK4/2 or a more general feature of CD8 ÷ anti- 
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Figure 3. Cold-Target Inhibition of Cytotoxicity by the Anti-JK50t Line 
to its Inducing Clone 
Cold-target inhibition was performed by using an assay mixture of the 
CD8 + anti-JK50t line as effector (10 ~ per well) and clone JK50t as 
labeled target (2 x 104 per well). Baseline killing at a 5:1 E:T ratio 
was 20%, as shown in Figure 2. The polyclonal VI~2 ÷ and V~2 lines 
shown in Figure 2 or clone JK50t were added as cold-target inhibitors 
at the indicated cold:labeled ratio an d the percent inhibition of cytotoxic 
release at 14 hr was determined as described in Experimental Proce- 
dures. 
bers. As shown in Figure 3, the JK50t clone was efficiently 
killed by the anti-JK50t parental cell line. Furthermore, a 
polyclonal VI32 ÷ CD4 ÷ population of cells (J K[TSST]) served 
as  an'effective cold-target inhibitor, in contrast, the poly- 
":C]0nal VI32- CD4 ~ line (JK[SEB]) did not significantly block 
'~ ~iysi~. Together, these data further support the notion that 
Figure 2. Specificity of a Polycional CD8 + Anti-JK50t Line the str'U(;ture'recognized on target cells by the  ant i - JK50t  
(a and b) Four VI~2* CD4 ~ lines and three VI32 CD4 ÷ lines were used " : pa.rental cel l  l ine and its subc lone  JK4 /2  is related to deter -  
as targets in a 14 hr ~'Cr release assay with graded numbers of the ~' ' minants common to mOB V~2 molecules. 
anti-JK50t line as effector. (t) and (s) designate V~,2 ÷ and VI~2 cloneS, : " 
respectively; JK(SEB)is an autologous CD4 + line raised to SEB (Vl32-); The Susceptibility of Target Cells to TCR 
JK(TSST) is a CD4+ line raised to TSST-1 (50% V~2+). ' " !"  i VI3-Di.rected Cytotox ic i ty  Is Dependent 
-": On their State of Activation 
CD4 ÷ T cells, we examined the reactivity of the parent l ine 
from which JK4/2 had been cloned. As shown in Figure 
2a, the anti-JKS0t parental line wa} cytotoxic toward 
cloned VI32 ÷ CD4 ÷ targets (JK50t, JK117t, and JK112t) as 
well as to a polyclonal VI32 ÷ CD4 ÷ T cell line (JK[TSST]), 
whereas it was minimally active against either cloned VI32 
CD4 ÷ targets (JKF8, JK202s) or to a polyclonal VI~2- CD4 ÷ 
target (JK[SEB]) (Figure 2b). The fact that the anti-JK50t 
line, which was raised against a single VI32 ÷ CD4 ÷ target, 
was cytotoxic to a polyclonal population of VI32 ÷ cells is 
suggestive that sequences shared by V~2 TCR are suffi- 
cient to identify a cell as a suitable target. Together with the 
clonal analysis described above, this further substantiates 
the idea that the target structure recognized by these CD8 ÷ 
T cells is a determinant shared by a large proportion of 
VI32 + cells. 
To study further the specificity of the anti-JK50t l ine,'we 
carried out cold-target inhibition assays using both c loned 
and polyclonal CD4 ÷ cells as the cold-target inhibitors. In 
these exl~eriments, the polyclonal anti-JK50t parental cell 
line was used as the effector and the inducing CD4 ÷ clone 
JK50t as the labeled target at a ratio of 5:1. Unlabeled 
potential cold-target inhibitors were added in graded num- 
During the course of these experiments, we noted that 
the sensitivity of V~2 ÷ CD4 ÷ T cells to lysis was related to 
the time between their restimulation with phorbol/ iono- 
mycin and analysis• To study this in greater detail, we 
determined the cytotoxicity of the anti-JK50t line towards 
a VI~2 ÷ CD4 ÷ (JK50t) and a VI32- CD4 ÷ (JK202s) clone over 
two sequential cycles of CD4 ÷ T cell stimulation. As shown 
in Figure 4, the TCR V~2 ÷ target was minimally lysed by 
the anti-JK50t line for the first 2 days following activation. 
Susceptibil ity was gained from day 3 to day 5 and was 
lost until 2 -3  days following the subsequent stimulation. 
On the other hand, the VI32- clone was not significantly 
killed at any time. This result supports the idea that the 
susceptibil ity of a CD4 ÷ T cell clone to lysis by autologous 
TCR Vl3-specific CD8 ÷ cells depends on the state of CD4 + 
T cell activation. 
Specific Reactivity of CD8 ÷ T Cells Toward 
Autologous CD4 + T Cells Is Not Unique 
to TCR Vp2-Expressing Targets 
To determine whether the phenomenon of CD8 ÷ T cell 
reactivity to autologous CD4 ÷ T cells is limited to TCR 
VI32-bearing T cells, we first isolated both VI32 ÷ and VI33 ÷ 
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Figure 4. Time Course of Sensitivity to Cytolytic Action 
The VJ~2 ÷ CD4 ÷ and VI~2- CD4 ÷ clones JK50t and JK202s, respectively, 
were used as targets in a 14 hr 51Cr release assay with the anti-JK50t 
line over two cycles of stimulation. Arrows indicate times of stimulation 
with phorbol/ionomycin. In parallel control experiments, the addition 
of ConA (25 ~g/ml) resulted in killing of all clones at all times (data 
not shown). 
CD4 ÷ clones from another donor. These CD4 + T cells 
clones were used to generate CD8 ÷ anti-CD4 clones by 
limiting dilution. CD8 ÷ T cells growing in response to the 
autologous CD4 ÷ clones were then screened for cytotoxic- 
ity against both the VI32 + and VI33 ÷ CD4 ÷ target clones 
(Figure 5). As shown, 9 of 14 CD8 ÷ clones raised against 
the VI33 ÷ CD4 ÷ clone TC3/1 showed greater cytotoxicity 
to the VI33 ÷ CD4 ÷ clone (TC3/1) than to the VI32 + CD4 ÷ 
clone (TC2/151). The five other clones raised to TC3/1 
showed less than 10% reactivity toward both targets. Re- 
ciprocally, 8 of 11 CD8 ÷ clones raised against the Vl32 ÷ 
CD4 ÷ clone showed greater cytotoxicity toward the VI32 ÷ 
clone than to the VI33 + target. Three clones had activity 
of less than 10%. From these experiments, we conclude 
that the Vl~-specific cytotoxicity of CD8 ÷ T cells to autolo- 
gous CD4 ÷ T cells is not limited to CD4 ÷ T cells expressing 
TCR VI~2. 
Moreover, we performed additional specificity studies 
on the anti-ViB2 clone, TC12/7. As with the anti-V132 sub- 
clone JK4/2 described above, TC12/7 showed maximal 
cytotoxicity to the inducing VI~2 ÷ CD4 ÷ clone, somewhat 
less to other independently isolated VI32 + CD4 + autologous 
clones, and little to an autologous clone using a different 
TCR VI3 (Figure 6). This result verifies in an independent 
donor that ViB-specific cytotoxicity of CD8 ÷ T cells to autolo- 
gous CD4 ÷ T cells is not strictly anti-idiotypic. 
The Interaction Between CD8 ÷ CTL and VJ~-Expressing 
CD4 + Cells Is Not Blocked by Antibody 
to Human HLA A/B/C Molecules 
Because CD8 ÷ CTL, usually recognize antigen in the con- 
text of class I M HC molecules, we asked whether the CD8 ÷ 
anti-CD4 + CTLs described in this paper also are depen- 
dent on the recognition of MHC class I molecules. We 
tested for possible MHC class I involvement in blocking 
experiments using the MAb W6/32, which is known to react 
with a nonpolymorphic determinant common to human 
HLA A/B/C molecules. Table 1 gives the result of five inde- 
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Figure 5. Reciprocal Specificity of T Cell Clones Induced by either 
VI32 + or V~3 ÷ CD4 + T Cells 
Anti-T cell clones were prepared by plating CD4- depleted PBL from 
donor TC in 96-well U-bottomed plates on the appropriate feeders as 
described in Experimental Procedures. Wells that grew sufficiently for 
testing were used as effectors in a 14 hr ~Cr release assay against 
the inducing VI32 ÷ (TC2/151) and V~3 + (TC3/1) clones. 
(a) Comparative cytotoxicity of CD8 ÷ clones expanded on TC3/1. 
(b) Comparative cytotoxicity of CD8 ÷ clones expanded on TC2/151. 
pendent experiments. The positive control for all five of these 
experiments consisted in assaying the capacity of W6/32 
to block the MHC class I -dependent  cytotoxicity of a CD8 + 
clone (TC9) against an autologous lymphoblastoid line. 
As shown (Table 1) in all experiments, W6/32 markedly 
blocked killing by the control clone TC9. As a negative 
isotype control, the MAb L243, which reacts with HLA class 
II molecules, had no effect (data not shown). Although W6/ 
32 effectively blocked the killing mediated by the MHC- 
dependent CD8 ÷ clone, it had no significant effect on the 
cytotoxicity of the V~2-specific CD8 + CTL clone (TC12/7) 
to its inducing VI~2 + CD4 + T cell target (Table 1). We also 
showed that inhibition is not masked by a concomitant 
antibody-dependent cellular cytotoxic reaction mediated 
by MAb W6/32, because the antibody did not induce lysis 
of the VI33 ÷ CD4 ÷ clone (TC3/1, experiment 3). Taken to- 
gether, these experiments how that the Vl3-specific CD8 ÷ 
anti-CD4 ÷ CTLs described here do not interact with the 
human HLA class I molecules recognized by W6/32. These 
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Figure 6. Specific Cytotoxicity of the CD8 + Clone TC12/7 
The CD8 ÷ clone TC12/7 shown in the screening in Figure 5 was tested 
for cytotoxicity in a 14 hr 'lCr release assay against its inducing CD4 + 
clone TC2/151, two independently isolated V~2 ÷ CD4 + clones (TC2/9 
and TC2/109), and the VI33 + CD4 + clone TC3/1. 
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Table 1. Failure of MAb W6/32 to Block Cytotoxicity of TC12/7 to its Inducing Clone* 
Experiment Number Effector:Target Pair Percent Cytotoxicity Percent Cytotoxicity +W6/32 Percent Inhibition 
1 12/7:2/151 28.2 34.6 <1 
Control:l: 61.0 19.6 68 
2 12/7:2/151 45.9 53.6 <t 
Control:l: 51.9 1.2 98 
3 12/7:2/151 23.4 26.8 <1 
12/7:3/11" 3.1 1.5 - 
ControH: 56.8 17.6 68 
4 12/7:2/151 16.9 15.5 12 
Control:l: 65.1 4.8 92 
5 12/7:2/151 37.6 35.0 7 
Control:l: 64.5 23.4 64 
* The two CD8 ÷ clones, TC 12/7 and TC9, were tested against their specific targets, TC2/151 and the lymphoblastoid line TC(LCL), respectively, 
in a 14 hr slCR release cytotoxic assay in the presence and absence of 20 p.g/ml MAb W6/32 (in preliminary experiments, 5 ~g/ml was sufficient 
to inhibit maximally the control cytotoxcity). Five independent experiments are shown. 
t In addition, in experiment 3, the target TC3/1 was included to rule out antibody-dependent cytotoxicity. 
~: The positive control for all five of these experiments consisted in assaying the capacity of W6/32 to block the cytotoxicity mediated by MHC 
class I-dependent cytotoxicity of a CD8 + clone (TC9) against autologous lymphoblastoid cells. As a negative isotype control, the MAb L243, which 
reacts with HLA class II molecules, had no effect (data not shown). 
data are consistent with the results in the accompanying 
paper showing that cytotoxicity mediated by murine VI3-spe- 
cific CD8 ÷ anti-CD4 + CTLs are not blocked by antibody 
recognizing conventional H-2 haplotypes (Jiang et al., 1995). 
Discussion 
In this paper, we provide evidence that TCR VI5 structures 
common to VI3 families expressed on the surfaces of CD4 ÷ 
T cells are involved in cytolytic interactions of human CD8 ÷ 
T cells with autologous CD4 ÷ T target cells. CD8 ÷ T cells 
were expanded using autologous clones and were found 
specifically to lyse the inducing CD4 ÷ T cell clone, as well 
as independently isolated autologous CD4 ÷ T cell clones 
and lines expressing the same but not a different TCR VI~ 
family. Of interest, CD4 ÷ T cell targets were susceptible 
to lysis for only a limited period of time fol lowing activation. 
Moreover, this VI3-specific cytotoxicity was not blocked by 
the MAb W6/32, which reacts with nonpolymorphic deter- 
minants present on HLA A/B/C class la molecules. Taken 
together, these results demonstrate the existence of CD8 ÷ 
T cells, precursors, or both in human peripheral blood that 
interact with CD4 ÷ T cells based on CD4 ÷ TCR VI3 usage. 
The VI3 specificity of the CD8 ÷ CTL was documented in 
a number of ways. First, we showed that CD8 ÷ T cells 
raised to VI32 + CD4 ÷ T cell c lones are cytotoxic in s1Cr 
release assays to autologous independently isolated VI~2 + 
CD4 ÷ clones, but not to autologous VI32- CD4 ÷ clones (Fig- 
ure 1; Figure 6). Specificity was further demonstrated in 
experiments showing that a CD8 ÷ line raised against a 
VI.~2 + CD4 ÷ clone was cytotoxic to other autologous VI32 + 
CD4 ÷ lines and clones but not to VI32- CD4 ÷ targets (Figure 
2). In addition, we showed that a polyclonal VI32 + line of 
CD4 + cells was an effective cold-target inhibitor of cytotox- 
icity of this line to the VI~2 ÷ CD4 ÷ clone used in its ex- 
pansion, whereas a VI32- line was not (Figure 3). Fina!ly, 
we demonstrated in a reciprocal cloning exper iment hat 
CD8 ÷ T cells raised against autologous CD4 + T cell clones 
with different TCR VI3 usage were cytotoxic to their induc- 
ing clone but not the reciprocal inducer. Taken together, 
these experiments indicate that CD8 ÷ T cells can kill autol- 
ogous CD4 ÷ T cells based, at least in part, on the recogni- 
tion of their Vl3 sequences. 
The precise composition of the target structure recog- 
nized by the CD8 ÷ cells described here is of considerable 
interest. Because they are CD8 ÷T cells, we initially consid- 
ered the possibility that they would interact with their target 
cells in the same manner as other antigen-specific CD8 ÷ 
T cells by recognizing peptide bound to a MHC class I 
molecule. The previous observations that human CD8 ÷ T 
cell clones can inhibit fresh autologous allo-reactive CD4 + 
cells in a class I MHC-restdcted manner is consistent with 
this notion (Koide and Engleman, 1990). In contrast, we 
found that the anti-MHC class I MAb W6/32 does not block 
the interaction of the VI3-specific CD8 ÷ clones with their 
autologous CD4 ÷ T cell targets (Figure 6). Because W6/ 
32 reacts with shared conformational determinants on the 
major class I molecules HLA A/B/C, our data strongly sug- 
gest that conventional MHC class I structures were not 
involved in the recognition by these CD8 ÷ T cell clones. 
This lack of inhibition by an anti-MHC class I antibody is 
similar to two other reports concerning the interaction of 
CD8 ÷ T cells with syngeneic CD4 ÷ T cells, which also sug- 
gest that class I is not involved. Sun et al. (1988) described 
a lack of inhibition by anti-class I antibody of a CD8 ÷ cell 
line specifically cytolytic to a myelin basic protein-respon- 
sive CD4 ÷ line in Lewis rats. Also in rats, Kimura and Wil- 
son (1984) have described CD8 ÷ anti-allo-reactive T cells 
that were not restricted by the class I type of the allo- 
reactive cells. Taken together, these studies raise the pos- 
sibility that other histocompatibil ity molecules might also 
be involved in the presentation of TCR peptides (Bloom 
et al., 1992a; Shinohara et al., 1988). In support of this, 
we show in the accompanying paper (Jiang et al., 1995) 
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in a murine system analogous to the human system de- 
scribed here, that an anti-MHC class la antibody also fails 
to block cytotoxicity of a VI38-specific CD8 + T cell line to its 
Vl38 + CD4 ÷ targets, whereas an antiserum directed toward 
molecules of the Class Ib histocompatibility locus, Qa-1, 
is an efficient inhibitor. In this regard, it will be of interest 
to study whether nonclassical MHC molecules, like CD1, 
HLA-G, HLA-E, and HLA-F are involved in the human stud- 
ies of the VI3-specific CD8 ÷ T cells described here. Never- 
theless, the combined results from both species suggest 
that CD8 ÷ T cells that recognize all or part of a TCR VI3 
chain on the surface of CD4 + cells independently of classi- 
cal class la can be isolated. 
Our finding that CD4 ÷ cells are not continuously subject 
to cytotoxicity by CD8 ÷ cells raised against them but can 
be efficiently killed for only a lim ited period of time following 
their activation (Figure 4) may be significant in understand- 
ing the potential relevance of this interaction in vivo. If 
present in vivo, the restricted period of sensitivity would 
serve to limit regulation to recently activated CD4 ÷ T cells. 
Thus, naive as well as memo ry T cells wou Id not be subject 
to the T-T cell interactions described here and in the ac- 
companying paper (Jiang et al., 1995). One possible expla- 
nation for this finding is that the TCR target structure itself 
is not continuously present on the CD4 ÷ T cell surface. For 
example, the expression of class I molecules on lymphoid 
cells is not constant. We have shown (unpublished ata) 
that the surface density of class I molecules on human 
CD4 ÷ T cell clones is transiently increased following activa- 
tion, as is susceptibility to lysis. In addition, certain MHC 
class Ib molecules in both humans and in mice are present 
only on activated, but not resting, lymphocytes (Paul et al., 
1987, Shawar et al., 1994). Class I molecule expression is 
also influenced by cytokines. 13 interferon, which has been 
shown to be effective in the treatment of multiple sclerosis 
(The IFNB Multiple Sclerosis Study Group, 1993), rapidly 
induces an increase in class I molecules on human CD4 ÷ 
T cells (unpublished data; Fellows et al., 1979), and in 
class I (Lindahl et al., 1974) and in Qa-1 molecules (unpub- 
lished data; Stanton and Carbon, 1983) on murine T cells. 
If MHC molecules of this type were utilized in the presenta- 
tion of a TCR-related target structure, recognition would 
depend on the state of activation of the CD4 ÷ T cell. On 
the other hand, the temporal sensitivity of CD4 ÷ cells may 
simply reflect an activation-dependent appearance of non- 
specific molecules required for adequate conjugate forma- 
tion or for apoptosis. In either case, our results show that 
CD4 ÷ cells are not targets for indiscriminate attack by VI3- 
specific CD8 ÷ cells simply on the basis of their TCR vari- 
able chain usage. 
Of equal importance to the overall target structure is the 
region of the CD4 ÷ TCR V~ molecule that is involved. Early 
models of immuneregulation i cluded often complex cir- 
cuitry involving interactions among T cells and soluble T 
cell factors based on idiotypic anti-idiotypic recognition 
(Dorf and Benacerraf, 1984). Some experiments in hu- 
mans have indicated that interactions among autologous 
T cells may occur on a purely clonotypic basis (Naor et 
ai., 1991). In contrast, recent experiments in which ani- 
mals were vaccinated with peptides representing portions 
of the VI3 determinants of a TCR molecule indicate that 
VI3 sequences can induce immunoregulatory events, in- 
cluding down-regulation of the CD4 ÷ cells expressing the 
corresponding TCR VI3 (Vandenbark et al., 1989; Howell 
et a1.,1989; Gaur et al., 1992, 1993). Whether clonotypic 
or Vl~-specific regulatory events predominate under con- 
ditions of natural immunization is currently under investi- 
gation in several laboratories. The results presented here, 
in which potentially regulatory CD8 + T cells are expanded 
in vitro using autologous T cell clones as the only stimulus, 
indicate that CD8 ÷ T cells responsive to CD4 ÷ cells purely 
on the basis of the CD4 ÷ VI~ chain exist. However, the 
cytotoxicity of these cells was greatest oward the inducing 
clone, but somewhat less to independently isolated clones 
and lines expressing the same TCR VI3 (Figure 1 ; Figure 
2; Figure 5; Figure 6). In the case of the polyclonal CD8 + 
effector cells, this specificity may reflect the presence of 
distinct clones directed toward either clonotypic or frame- 
work specificities of the inducer cell. However, the obser- 
vation that in two subcloned effector clones this same pref- 
erence for the inducer clones was observed suggests the 
possibility that the TCR VI3 sequences recognized may 
involve both clonotypic as well as nonclonotypic regions. 
In this regard, it is of interest that in the murine system it 
has recently been shown that following immunization with 
myelin basic protein, CD4 ÷ T cells arise that proliferate in 
response to peptides representing framework sequences 
of the TCR Vl38.2 molecule, but only to those sequences 
that are near the junctional region (Kumar and Sercarz, 
1993). Additional fine structural analysis will be required 
to define the precise contribution of different regions of 
TCR variable regions to the T-T cell interactions involved 
in the murine studies as well as in the human. 
Although the in vivo significance of the CD8 ÷ T cells 
described here is presently unknown, it is of interest that 
there have been a number of recent reports in animal sys- 
tems regarding the ability of CD8 ÷ cells to regulate the 
immune response of CD4 ÷ cells on the basis of their TCR. 
In rats and in mice, EAE is directly caused by myelin basic 
protein-responsive CD4 ÷ cells utilizing primarily the VI38.2 
TCR (Kumar and Sercarz, 1993; Sun et al., 1988). Mice 
that recover from this disease are protected both from 
relapses and from a second induction by immunization 
with myelin basic protein, but only if they possess CD8 ÷ 
cells (Jiang et al., 1992; Koh et al., 1992). Similarly, vacci- 
nation of mice with a peptide representing the CDR2 re- 
gion of the TCR Vl38.2 molecule leads to functional inacti- 
vation of all VI38.2 + CD4 ÷ cells, but not V1~8.2- CD4 ÷ cells, 
only in the presence of a normal population of CD8 + cells 
(Gaur et al., 1993). More recently, it has been shown that 
clones of CD4 + cells with reactivity to certain peptides of 
the TCR VI38.2 molecule can adoptively transfer resis- 
tance to induction of EAE in mice only if the recipient ani- 
mals have CD8 ÷ cells (Kumar and Sercarz, 1993). Finally, 
the accompanying paper (Jiang et al., 1995) demonstrates 
that the prolonged depletion of peripheral VI38 ÷ CD4 ÷ T 
cells that follows the administration of SEB is inhibited 
by in vivo treatment with anti-CD8 MAb. Thus, in several 
different mammalian systems it has been shown that im- 
mune regulation by the classical suppressor/cytotoxic 
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subset  of CD8 ÷ cells is directed towards CD4 ÷ cells that 
share TCR variable chain sequences.  The results pre- 
sented  here and in the accompany ing  paper  (Jiang eta l . ,  
1995), showing direct interaction in vitro between CD8 ÷ 
and CD4 + cells based on the TCR V~ usage of the CD4 ÷ 
cells, provide a possible mechan ism for these observa- 
tions. 
Experimental Procedures 
Isolation of Lymphocyte Subsets and CD4 ÷ Clones 
Peripheral blood lymphocytes (PBL) were isolated as described (Fried- 
man et al., 1981). In brief, PBL were isolated from healthy donors by 
sedimentation of heparinized blood over Histopaque (Sigma Chemical 
Company, St. Louis, Missouri). CD8-- cell fractions were prepared by 
incubating 10 x 10 ~ freshly isolated PBL with 15 x 10 e anti-CD4- 
coated magnetic beads for 30 min at room temperature. Beads and 
adherent CD4 + cells were removed by magnetic separation (Dynal, 
Incorporated, Lake Success, New York). Depletion was monitored by 
cytofluorographic analysis and repeated if CD4 ÷ cells represented 
greater than 1% of the remaining population. SEB and TSST-1 respon- 
sive clones were isolated by limiting dilution plating of freshly isolated 
PBL added to irradiated (2000 fads) autologous PBL (105 cells/well) 
in 96-well U-bottomed plates (Nunc, Incorporated, Naperville, Illinois) 
in medium consisting of IMDM, 10% autologous erum, 1% penicillin- 
streptomycin, and 100 ng/ml toxin (Toxin Technology, Madison, Wis- 
consin). Isolation of CD4 + clones by FACS sorting was accomplished 
as described (Danglet al., 1982). Freshly isolated PBLs were stained 
with saturating amounts of MAbs to CD8 (fluorescein isothiocyanate 
conjugated) and to either TCR VJ32 or TCR VJ~3 (biotin conjugated) 
and separated on a FACS (Becton Dickinson, San Jose, California). 
Cells were gated to select CD8 cells of a defined V~ phenotype and 
sorted into 96-well U-bottomed plates containing 105 irradiated autolo- 
gous PBL/well in 0.1 ml of medium. Independent of the method of 
cloning, interleukin-2 (IL-2)(Chiron Corporation, Emeryville, California) 
was added after 6 days of culture and, after 10-14 days, proliferating 
wells were screened for CD4 ÷ and TCR V~ usage. Selected wells were 
subcloned at limiting dilution by stimulation with superantigen or OKT3 
and maintained subsequently by weekly stimulation using phorbol di- 
butyrate (20 ng/ml) and ionomycin (.4 ~M for 6 hr at 37°C; both from 
Sigma Chemicals). 
Generation of Autologous CD8 + Anti-CD4* T Cell 
Clones and Lines 
CD8 + lines directed against chosen CD4 + clones were raised by incu- 
bating 10 x 106 freshly isolated CD4 + depleted PBL and 5 x 108 
irradiated (2000 rads) CD4 ÷ inducer clones in 50 cc flasks (Costar 
Corporation, Cambridge, Massachusetts) in 15 cc of medium con- 
sisting of IMDM, 10% autologous erum, and 1% penicillin-streptomy- 
cin. CD8 + clones against chosen CD4 + T cell clones were raised by 
incubating 5 x 104 freshly isolated CD4 ÷ T cell-depleted PBL, 10 s 
irradiated autologous PBL, and 5 x 104 irradiated CD4 + cloned T 
cells per well of a 96-well U-bottomed plate in the same medium. 
Recombinant IL-2 (30 U/ml) was added 6 days later. Clones were 
screened for cytotoxicity to the inducing clone and either an autologous 
lymphoblastoid line or an autologous CD4 ÷ clone with a different TCR 
VI3 and subcloned. Lines and clones were maintained by stimulation 
every 2 weeks with a mixture of irradiated autologous PBL feeders 
and the inducing clone in medium containing 30 U/ml IL-2. 
Cytotoxic Assays 
5~Cr Release Assay 
51Cr release assays were carried out as described (Friedman etal., 
1981). In brief, 4 days after stimulation CD4 ÷ target cells were labeled 
with 200 p.Ci 5~Cr (New England Nuclear, Boston, Massachusetts) for 
60 min and placed at 2 x 104 per well in 96-well U-bottomed plates 
(Nunc, Incorporated, Naperville, III inois) in triplicate. Effector cells (10 ~) 
(5:1 E:T ratio) were added, and incubation was carried out at 37°C 
for 14 hr. Supernatant was harvested and counted in an LKB ~f counter 
(Pharmacia, Gaithersburg, Maryland). The percent specific ~Cr re- 
lease was calculated as 
(sample - spontaneous) / (total - spontaneous) x 100 
In antibody-blocking experiments, 51Cr release assays were carried 
out as described in the presence and absence of 20 pg/ml purified 
W6/32 antibody. Targets were incubated with antibody 60 min before 
addition of the effector cell in all cases, 
Cold Target Inhibition Assay 
Effector cells (105 per well) (anti-JK50t) were added to 2 x 104 per 
well SlCr-labeled targets (JK50t) in the presence of graded numbers 
of an unlabeled inhibitor T cell line (ranging from 5 x 104 to 4 x 10~/ 
well). All assays were carried out in triplicate as above. Specific 51Cr 
release was determined and the percent inhibition calculated as 
(Co - Ci) / Co x 100 
where Co is the cytotoxicity in the absence and Ci the cytotoxicity in 
the presence of the cold-target inhibitor. 
Cytofluorographic Analysis 
The methods utilized for cytofluorographic analysis have been de- 
scribed previously (Lederman etal., 1992). In brief, cells were first 
treated with aggregated human immunoglobulin (Enzyme Interna- 
tional, Fallbrook, California)to block nonspecific immunoglobulin bind- 
ing. Cells (5 x 104) were incubated with saturating concentrations of 
the indicated directly coupled MAbs for 10 rain at 4°C and rinsed in 
the presence of propidium iodide (25 p,g/ml) to eliminate dead cells 
from analysis. Fluorescence intensity was measured on a FACScan 
cytofluorograph (Becton Dickinson). 
Antibodies 
Antibodies to human CD3, CD4, and CD8 conjugated to fluorescein 
isothionate were purchased from Becton Dickinson. Antibodies to TCR 
V~2 and TCR V[33 conjugated to biotin were purchased from Amac, 
Incorporated (Westbrook, Maine). Hybridomas producing the MAbs 
W6/32, L243, and OKT3 were purchased from American Tissue Cul- 
ture Collection (Rockville, Maryland). Ascites containing these antibod- 
ies was produced and purified as described (Lederman et al., 1992). 
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